Cargando…
Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
BACKGROUND: Drug-drug interactions (DDIs) in subjects enrolling in clinical trials can impact not only safety of the patient but also study drug outcomes and data validity. This makes it critical to adequately screen and manage DDIs. The study objective was to determine the prevalence of DDIs involv...
Autores principales: | Marcath, Lauren A., Coe, Taylor D., Hoylman, Emily K., Redman, Bruce G., Hertz, Daniel L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249716/ https://www.ncbi.nlm.nih.gov/pubmed/30466416 http://dx.doi.org/10.1186/s12885-018-5076-0 |
Ejemplares similares
-
Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
por: Marcath, Lauren A., et al.
Publicado: (2021) -
Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics
por: Marcath, Lauren A., et al.
Publicado: (2018) -
A Database of Drug Repurposing Clinical Trials in Oncology
por: Pantziarka, Pan, et al.
Publicado: (2021) -
Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology
por: Kurtin, Sandra E., et al.
Publicado: (2020) -
Phase 0 clinical trials in oncology new drug development
por: Gupta, Umesh Chandra, et al.
Publicado: (2011)